/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

T

Taroh Satoh

Osaka City University(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

526

Papers

25.2K

Citations

55

h-index

191

i10-index

Taroh Satoh is an academic researcher from Osaka City University. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Gastric Cancer Management and Outcomes & Lung Cancer Treatments and Mutations. The author has an h-index of 55, co-authored 448 publications.

ORCID: 0000-0002-4615-2638

Research Topics

Colorectal Cancer Treatments and Studies Gastric Cancer Management and Outcomes Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research

Papers by this author

works

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

2010 · The Lancet · 7,196 citations

https://doi.org/10.1016/s0140-6736(10)61121-x

Yung‐Jue Bang Eric Van Cutsem A. Feyereislova Hyun Cheol Chung

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

2023 · The Lancet · 891 citations

https://doi.org/10.1016/s0140-6736(23)00727-4

Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S. Finn

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

2011 · Science Translational Medicine · 661 citations

https://doi.org/10.1126/scitranslmed.3002442

Kimio Yonesaka Kreshnik Zejnullahu Isamu Okamoto Taroh Satoh

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

2014 · Journal of Clinical Oncology · 616 citations

https://doi.org/10.1200/jco.2013.53.6136

Taroh Satoh Rui‐Hua Xu Hyun Cheol Chung Guoping Sun

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

2017 · The Lancet Oncology · 379 citations

https://doi.org/10.1016/s1470-2045(17)30181-x

Toshihiro Kudo Yasuo Hamamoto Ken Kato Takashi Ura

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

2023 · The Lancet · 279 citations

https://doi.org/10.1016/s0140-6736(23)00772-9

Arvind Dasari Sara Lonardi Rocio García‐Carbonero Élena Elez

Research topics

topics

Colorectal Cancer Treatments and Studies

Gastric Cancer Management and Outcomes

Lung Cancer Treatments and Mutations

Cancer Immunotherapy and Biomarkers

Pancreatic and Hepatic Oncology Research

Chat about Author

Papers

Chat

Click to start Chat